| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgements
|
|
|
|
31 |
S5 |
p. x
|
artikel
|
| 2 |
CRUK
|
|
|
|
31 |
S5 |
p. viii
|
artikel
|
| 3 |
Editorial Board
|
|
|
|
31 |
S5 |
p. i
|
artikel
|
| 4 |
ESMO
|
|
|
|
31 |
S5 |
p. vi
|
artikel
|
| 5 |
1MO A proteomics-based platform for predicting response to immunotherapy and personalising treatment plans
|
Shaked, Y.
|
|
|
31 |
S5 |
p. S1217
|
artikel
|
| 6 |
4MO MET exon 14 screening strategy: How not to miss large deletions
|
Loyaux, R.
|
|
|
31 |
S5 |
p. S1218
|
artikel
|
| 7 |
3MO Mutational signatures in the perspective of tumour mutational burden in patients with non-small cell lung cancer
|
Van den Heuvel, G.
|
|
|
31 |
S5 |
p. S1217-S1218
|
artikel
|
| 8 |
2MO Radiotherapy in cancer is associated with a deletion signature that contributes to poor patient outcomes
|
Kocakavuk, E.
|
|
|
31 |
S5 |
p. S1217
|
artikel
|
| 9 |
Notice and Disclaimer
|
|
|
|
31 |
S5 |
p. iii
|
artikel
|
| 10 |
58P An atypical late-onset case of homozygous ATM variant supported by a complex molecular mechanism of mosaic uniparental isodisomy
|
Nambot, S.
|
|
|
31 |
S5 |
p. S1235
|
artikel
|
| 11 |
73P Anti-angiokinases in patient-specific combination regimens can improve outcomes in advanced metastatic cancers
|
Patil, D.
|
|
|
31 |
S5 |
p. S1238
|
artikel
|
| 12 |
19P A prospective study about BRCA1/BRCA2 germline mutations in hereditary breast /ovarian cancer patients
|
Ben Kridis, W.
|
|
|
31 |
S5 |
p. S1223
|
artikel
|
| 13 |
65P Association of SNPs at 10q21-25 chromosome in patients with colorectal cancer in the Kazakhstan population
|
Kolesnichenko, S.
|
|
|
31 |
S5 |
p. S1236-S1237
|
artikel
|
| 14 |
7P Comparison of the clinical utility of two different size next generation sequencing (NGS) gene panels for solid tumours
|
Özdemir, B.
|
|
|
31 |
S5 |
p. S1219
|
artikel
|
| 15 |
40P Correlation of IL-1-β-serum concentration with the number of leukocytes in peripheral blood in patients with solid tumours before immune checkpoint inhibitors therapy
|
Malkova, A.M.
|
|
|
31 |
S5 |
p. S1229
|
artikel
|
| 16 |
61P CRISPR/Cas9 and bioinformatics approaches revealed new regulators of pancreatic cancer cells platinum sensitivity
|
Skripova, V.
|
|
|
31 |
S5 |
p. S1235-S1236
|
artikel
|
| 17 |
60P Curbing the interplay between miR-939-5p and HEIH lncRNA by EGCG represses hydrogen sulphide machinery and hinders breast cancer progression
|
Nafea, H.
|
|
|
31 |
S5 |
p. S1235
|
artikel
|
| 18 |
17P Cyclophosphamide influence on survival probability of breast cancer patients depending on leukotriene receptor LTB4R gene expression level
|
Kalinkin, A.I.
|
|
|
31 |
S5 |
p. S1222
|
artikel
|
| 19 |
62P Cytoplasmic actin isoforms influence on CSC-like properties
|
Dugina, V.
|
|
|
31 |
S5 |
p. S1236
|
artikel
|
| 20 |
27P Development of DNA methylation markers panels for neoadjuvant chemotherapy response prediction in triple-negative breast cancer
|
Sigin, V.O.
|
|
|
31 |
S5 |
p. S1225
|
artikel
|
| 21 |
23P Different profile of receptor tyrosine kinases expression in breast cancer molecular subtypes
|
Babyshkina, N.
|
|
|
31 |
S5 |
p. S1224
|
artikel
|
| 22 |
25P DNA methylation biomarkers of clear cell renal carcinoma
|
Kubiliute, R.
|
|
|
31 |
S5 |
p. S1224-S1225
|
artikel
|
| 23 |
21P Double immunofluorescence (dIF) in analysing protein coexpression in tumours
|
Puchinskaya, M.
|
|
|
31 |
S5 |
p. S1223
|
artikel
|
| 24 |
37P Dysregulation of soluble immune checkpoint proteins in newly diagnosed early breast cancer patients
|
Rapoport, B.L.
|
|
|
31 |
S5 |
p. S1228
|
artikel
|
| 25 |
48P EAPC-36: A potent microtubule-targeting agent active against a broad spectrum of solid tumours
|
Boichuk, S.
|
|
|
31 |
S5 |
p. S1232
|
artikel
|
| 26 |
45P Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Pooled analysis of clinical trials and early access programs
|
Droz Dit Busset, M.
|
|
|
31 |
S5 |
p. S1231
|
artikel
|
| 27 |
63P EGFR and cellular proliferation in cervical cancer
|
Dumitru, M.
|
|
|
31 |
S5 |
p. S1236
|
artikel
|
| 28 |
12P EGFR gene mutations landscape at lung cancer in a multinational region located in the southeast of the European part of Russia
|
Sultanbaev, A.
|
|
|
31 |
S5 |
p. S1220-S1221
|
artikel
|
| 29 |
13P Evaluating targeted next-generation sequencing (NGS) assays and reference materials for NTRK fusion detection
|
Bormann Chung, C.
|
|
|
31 |
S5 |
p. S1221
|
artikel
|
| 30 |
67P Evaluation of genetic variants in miR-146-a, miR-618, and miR-181b as risk factors of colorectal cancer in Bulgarian patients
|
Radanova, M.
|
|
|
31 |
S5 |
p. S1237
|
artikel
|
| 31 |
55P Evaluation of MDM2-p53 antagonists, nutlin-3 and RG7388, combined with the PARPi rucaparib in primary cultures of ovarian cancer
|
Zanjirband, M.
|
|
|
31 |
S5 |
p. S1234
|
artikel
|
| 32 |
68P Exhaled breath analysis of volatile organic compounds (VOC) in diagnosis of lung cancer a meta-analysis
|
Bohra, A.
|
|
|
31 |
S5 |
p. S1237-S1238
|
artikel
|
| 33 |
28P Expression and prognosis characteristics of m6A RNA methylation regulators in breast cancer
|
Zhang, B.
|
|
|
31 |
S5 |
p. S1225
|
artikel
|
| 34 |
18P Expression of biomarkers of malignant pleural mesothelioma (MPM) over five years from 2015 to 2019 at Pham Ngoc Thach Hospital
|
Lam, N.S.
|
|
|
31 |
S5 |
p. S1222
|
artikel
|
| 35 |
15P Expression of CD30 in diffuse large B-cell lymphoma
|
Liasnichaya, O.V.
|
|
|
31 |
S5 |
p. S1221
|
artikel
|
| 36 |
38P Frequent changes in the environment can lead to heterogeneity of tumour cells
|
Burlaka, D.
|
|
|
31 |
S5 |
p. S1228-S1229
|
artikel
|
| 37 |
57P Functional inactivation of E-cadherin by Trop-2 drives cancer metastasis
|
Alberti, S.
|
|
|
31 |
S5 |
p. S1234-S1235
|
artikel
|
| 38 |
9P Gender and molecular aspects of molecular-guided therapy recommendations for therapy refractory head and neck cancers
|
Taghizadeh, H.
|
|
|
31 |
S5 |
p. S1219-S1220
|
artikel
|
| 39 |
10P Gender differences in molecular-guided therapy recommendations for metastatic malignant mesothelioma
|
Taghizadeh, H.
|
|
|
31 |
S5 |
p. S1220
|
artikel
|
| 40 |
46P Gold nanoparticles as radiosensitizers for human colon carcinoma cells
|
Glazunova, V.
|
|
|
31 |
S5 |
p. S1231
|
artikel
|
| 41 |
59P Hesperitin halts metastatic breast cancer through tweaking the interplay between the tumour suppressor miR-486-5p and the oncogenic lncRNA H19
|
Abdallah, R.
|
|
|
31 |
S5 |
p. S1235
|
artikel
|
| 42 |
66P High incidence of TP53 and epigenetic modifying oncogene mutations in a large cohort of patients enrolled in phase I clinical trials for R/R DLBCL
|
Quivoron, C.
|
|
|
31 |
S5 |
p. S1237
|
artikel
|
| 43 |
32P High levels of stromal tumour infiltrating lymphocytes, CD3, CD8 cells and Immunoscore® are associated with pathological CR and time to progression in TNBC patients undergoing neo-adjuvant chemotherapy
|
Rapoport, B.L.
|
|
|
31 |
S5 |
p. S1226-S1227
|
artikel
|
| 44 |
5P Hormonal biomarkers can improve prediction of response to hormonal therapy in advanced and recurrent endometrial cancer: Results of the PROMOTE-R study
|
Van Weelden, W.J.
|
|
|
31 |
S5 |
p. S1218
|
artikel
|
| 45 |
42P Imatinib mesylate (IM) promotes malignant behaviour of IM-resistant gastrointestinal stromal tumours (GISTs) via activation of FGF-signaling
|
Boichuk, S.
|
|
|
31 |
S5 |
p. S1230
|
artikel
|
| 46 |
26P Impact of 17q21 locus gene co-amplification on overall survival in HER2-positive breast cancer
|
Gaughran, G.
|
|
|
31 |
S5 |
p. S1225
|
artikel
|
| 47 |
47P Improved treatment outcomes by using patient-specific drug combinations in mTOR activated advanced metastatic cancers
|
Akolkar, D.
|
|
|
31 |
S5 |
p. S1232
|
artikel
|
| 48 |
24P Is molecular characterization useful for targeted therapy orientation in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) included in early phase clinical trials?
|
Michot, J-M.
|
|
|
31 |
S5 |
p. S1224
|
artikel
|
| 49 |
53P Light-driven photoswitching of novel combretastatin A-4 analogues: Therapeutic targeting of epidermoid carcinoma cells
|
Salnikova, D.I.
|
|
|
31 |
S5 |
p. S1233
|
artikel
|
| 50 |
33P Microenvironment of various morphological structures of breast cancer contribute to functional properties of tumour cells
|
Tashireva, L.
|
|
|
31 |
S5 |
p. S1227
|
artikel
|
| 51 |
16P Molecular analysis for precision oncology of children: Beyond genomics
|
Paret, C.
|
|
|
31 |
S5 |
p. S1222
|
artikel
|
| 52 |
43P Molecular mechanisms related to chemoresistance of colorectal cancer cells
|
Novoa Díaz, B.
|
|
|
31 |
S5 |
p. S1230
|
artikel
|
| 53 |
11P Molecular profiling and targeted therapy in cholangiocarcinoma
|
de Santayana, M. García Pardo
|
|
|
31 |
S5 |
p. S1220
|
artikel
|
| 54 |
20P Next generation sequencing and associated treatment changes: Results from Ireland East Hospital Group
|
Chew, S.
|
|
|
31 |
S5 |
p. S1223
|
artikel
|
| 55 |
22P Next generation sequencing-based molecular profiling of lung carcinoma: A routine care experience
|
Polivka, J.
|
|
|
31 |
S5 |
p. S1223-S1224
|
artikel
|
| 56 |
34P N-glycosylation status of membrane phosphate transporter NaPi2b is crucial for its epitope recognition by monoclonal antibody in tumour cells
|
Kiyamova, R.
|
|
|
31 |
S5 |
p. S1227-S1228
|
artikel
|
| 57 |
64P Notch- and P53-dependent crosstalk between tumour and stromal cells
|
Novikova, M.V.
|
|
|
31 |
S5 |
p. S1236
|
artikel
|
| 58 |
44P Novel insights into the pharmacological effects of hypoxic cytotoxins in hormone-dependent breast cancer cells: ERα degradation and modulation of ERK signaling activity
|
Scherbakov, A.M.
|
|
|
31 |
S5 |
p. S1230
|
artikel
|
| 59 |
14P Pharmacogenomic signature for dasatinib response in prostate cancer: A precision medicine initiative
|
Grover, A.
|
|
|
31 |
S5 |
p. S1221
|
artikel
|
| 60 |
36P Pro-oncogenic status of circulating neutrophils in cervical intraepithelial neoplasia
|
Abakumova, T.
|
|
|
31 |
S5 |
p. S1228
|
artikel
|
| 61 |
50P Retinoic acid signalling pathway as a putative therapeutic vulnerability in mouse models of pancreatic cancers characterised by DNA damage response deficiencies
|
Yong, S.Q.
|
|
|
31 |
S5 |
p. S1232-S1233
|
artikel
|
| 62 |
8P STC1, a baseline predictive biomarker for overall survival in metastatic colorectal cancer (mCRC)
|
Wespiser, M.
|
|
|
31 |
S5 |
p. S1219
|
artikel
|
| 63 |
41P Stem-like tumour cell populations and cytokine profile of the ascitic fluid in ovarian cancer
|
Gening, S.
|
|
|
31 |
S5 |
p. S1229-S1230
|
artikel
|
| 64 |
51P Targeting carbonic anhydrase IX with novel isatin-5-sulphonamides: A way forward to control tumour acidosis
|
Krymov, S.
|
|
|
31 |
S5 |
p. S1233
|
artikel
|
| 65 |
49P Targeting IGF1R in osteosarcoma
|
Vewinger, N.
|
|
|
31 |
S5 |
p. S1232
|
artikel
|
| 66 |
39P TGF-β1 and TNF-α: Antagonistic cytokines controlling extracellular matrix remodeling after radioactive iodine therapy for papillary thyroid carcinoma
|
Stanciu, A.E.
|
|
|
31 |
S5 |
p. S1229
|
artikel
|
| 67 |
54P The combination of copper oxide nanoparticles and N-acetyl-L-cysteine triggers rapid oxidative burst and death of wild-type and multidrug-resistant tumour cells
|
Tsymbal, S.
|
|
|
31 |
S5 |
p. S1233-S1234
|
artikel
|
| 68 |
52P The complexities of the delivery of an RNA sequencing service for FFPE solid tumour samples within an NHS setting
|
Roberts, H.
|
|
|
31 |
S5 |
p. S1233
|
artikel
|
| 69 |
29P The evolving impact of genomic biomarker landscape in stage II colorectal cancer (CRC)
|
Arrivi, G.
|
|
|
31 |
S5 |
p. S1226
|
artikel
|
| 70 |
6P The importance of biomarker expression in addition to lymph node status in the ESMO risk stratification of endometrial cancer
|
Vrede, S.
|
|
|
31 |
S5 |
p. S1218-S1219
|
artikel
|
| 71 |
31P The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
|
Jiang, L.
|
|
|
31 |
S5 |
p. S1226
|
artikel
|
| 72 |
35P The tumour cells of various morphological structures are possible to modulate the immune-inflammatory reactions in invasive breast carcinoma
|
Buzenkova, A.
|
|
|
31 |
S5 |
p. S1228
|
artikel
|
| 73 |
30P T1N3 breast cancers (BC): Clinico-pathological analysis of tumours with early metastatic spread
|
Puchinskaya, M.
|
|
|
31 |
S5 |
p. S1226
|
artikel
|
| 74 |
56P tNOX and Sirt1 as potential targets of antitumor action of heliomycin derivatives
|
Tikhomirov, A.
|
|
|
31 |
S5 |
p. S1234
|
artikel
|
| 75 |
Table of Contents
|
|
|
|
31 |
S5 |
p. v
|
artikel
|
| 76 |
69TiP A pilot study of combined biomarker-based treatment strategies in patients with recurrent/metastatic squamous cell carcinoma of the cervix: RAIDS molecular targets trial for cervical cancer
|
Bello Roufai, D.
|
|
|
31 |
S5 |
p. S1238
|
artikel
|
| 77 |
71TiP P16 protein expression as a predictive biomarker for response to neoadjuvant chemotherapy in osteosarcoma
|
Babbar, P.N.
|
|
|
31 |
S5 |
p. S1239
|
artikel
|
| 78 |
72TiP Predictive value of tumour infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancer
|
Babbar, P.N.
|
|
|
31 |
S5 |
p. S1239
|
artikel
|
| 79 |
70TiP Tyrosine kinase inhibitors and lung cancer: History, epidemiology and market outlook
|
Miles, B.L.
|
|
|
31 |
S5 |
p. S1239
|
artikel
|
| 80 |
Title Page
|
|
|
|
31 |
S5 |
p. iv
|
artikel
|
| 81 |
Unicancer
|
|
|
|
31 |
S5 |
p. vii
|
artikel
|
| 82 |
Virtual Congress 2020 Officers
|
|
|
|
31 |
S5 |
p. ix
|
artikel
|
Tijdschrift beschrijving